Navigation Links
Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
Date:9/17/2007

Next-Generation Once-Daily CCR5 Antagonist Designed to Block HIV Infection

of Immune System Cells

KENILWORTH, N.J., Sept. 17 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that it has initiated two large Phase III clinical studies with vicriviroc, its investigational CCR5 antagonist, administered once-daily as a single 30 mg tablet in combination with an optimized background therapy that must include a protease inhibitor boosted by ritonavir in adult treatment-experienced HIV patients with R5-type virus only. Vicriviroc is a next-generation extracellular inhibitor of HIV infection designed to block entry of infectious virions into uninfected CD4 cells via antagonism of the CCR5 co-receptor.

The vicriviroc Phase III clinical program builds upon previous studies in HIV treatment-experienced patients, including a Phase II study (ACTG 5211) in which vicriviroc demonstrated potent and sustained viral suppression through 48 weeks of therapy.(1)

The two Phase III studies, known as VICTOR-E3 and VICTOR-E4 (Vicriviroc in Combination Treatment with an Optimized Antiretroviral Therapy Regimen in HIV- Infected Treatment-Experienced Subjects), will evaluate the virologic benefit of adding vicriviroc 30 mg once daily to an optimized background therapy compared to a control group receiving new optimized background therapy alone. The studies will also evaluate the safety and tolerability of vicriviroc compared to placebo. The optimized background therapy must include at least two drugs that are active, based on susceptibility testing. Patients coinfected with hepatitis C may be included in the studies and there are no exclusions of commonly prescribed drug
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
2. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
3. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
4. Malvern initiates European user group meetings for chemical imaging
5. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... SAN DIEGO , Dec. 18, 2014  RESMED INC. ... report its second quarter of fiscal year 2015 results on ... market close. A press release with ResMed,s results will be ... will host a webcast to discuss operating results and future ... at 1:30 p.m. US Pacific Time and the live webcast ...
(Date:12/19/2014)... , Dec. 19, 2014  Eli Lilly and ... Paris: FR0011184241 – ADOC) today announced a worldwide licensing ... BioChaperone Lispro, for treatment in people with type 1 ... proprietary BioChaperone® technology and is currently in Phase Ib ... Lispro with the goal of optimizing glucose levels during ...
(Date:12/17/2014)... Revenue and earnings above the previous year - ... In the past 2013/14 fiscal year (ended 30 September ... 4.287 billion (last year: EUR 4.190 billion) despite unfavorable currency ... million. "Overall, 2013/14 was a successful fiscal year for the ... CEO of Carl Zeiss AG. "Thanks to our broad portfolio ...
Breaking Medicine Technology:ResMed To Announce Second Quarter 2015 Results 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3ZEISS Asserts its Position in Difficult Environment 2
... Holdings, Inc. ("Bacterin") (OTC Bulletin Board: BIHI ... announced that it launched its OsteoSponge®SC product at the ... taking place February 15-19 in San Diego, CA.  Based ... the Food and Drug Administration to market OsteoSponge®SC as ...
... Feb. 16, 2011 MedAptus®, the market leader ... England Baptist Hospital (NEBH) has selected the company,s ... medicine providers. The NEBH hospitalist team, comprised of ... Inpatient Edition via the web as well as ...
Cached Medicine Technology:Bacterin International to Announce Launch of OsteoSponge®SC at American Academy of Orthopedic Surgeons 2011 Annual Meeting February 15-19 2Bacterin International to Announce Launch of OsteoSponge®SC at American Academy of Orthopedic Surgeons 2011 Annual Meeting February 15-19 3Hospitalists at New England Baptist Hospital Choose MedAptus 2
(Date:12/20/2014)... Francisco, CA (PRWEB) December 20, 2014 ... Social Innovation company just launched first birthday focused portal ... services, “MERRY BIRTHDAY MESSAGE” launched in both US and ... MERRY BIRTHDAY MESSAGE : http://merrybirthday.net/message/ , MERRY ... for everyone’s birthday around the world. , Features, Choose ...
(Date:12/20/2014)... Xarelto bleeding lawsuits filed by men ... and other serious side effects will be consolidated in ... coordinated pretrial proceedings, Wright & Schulte LLC reports. The ... order Friday to transfer 21 Xarelto lawsuits and over ... to the Louisiana district court for coordination by Judge ...
(Date:12/19/2014)... Today, Balfleet.com , a leading ... its formal dress promotion. All the old and new ... off. , Balfleet.com is well-known for its high quality ... dresses, cocktail dresses and more. Its formal dresses are ... and they can create an elegant look when paired ...
(Date:12/19/2014)... Tampa, FL (PRWEB) December 19, 2014 ... Celliant Revitalizing Bedsheets are now available. Celliant, the ... in both sheets and pillowcases. , There are ... clinically proven additional circulation, increased oxygenation and balanced ... quality, faster healing and pain relief; enhanced athletic ...
(Date:12/19/2014)... Canadian, OK (PRWEB) December 19, 2014 ... is home to Lake Eufaula, the state’s largest lake ... lovely lakeside town is home to a little more ... at 1:00 P.M. on Saturday, the 6th of December. ... made its way through downtown Eufaula on Main Street. ...
Breaking Medicine News(10 mins):Health News:Atore, Inc. Releasing the First Birthday Portal 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 3Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 4Health News:Balfleet.com Announces Its Formal Dress Promotion For 2015 2Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 3
... on June 11th, during Games for Health Conference in Boston, MA ... you take care of your brain when every week brings a ... other? Do supplements improve memory? Do you need both physical and ... training approach, if any, is worth your time and money? ...
... New York Hospital Queens One of Clinical Sites, Research Director is ... the world,s most respected medical journals, the New England Journal ... explores treatments for people with both Type 2 diabetes and coronary ... Hospital Queens was one of the sites that conducted this study. ...
... Carl D. Stevens, MD, MPH, a researcher at Los ... BioMed), recently received the Award for Excellence in Education ... at the University of California, Los Angeles (UCLA) established ... excellence in education." Dr. Stevens is a ...
... places where young women outnumber young men, research shows the ... men feel less pressure to settle down as more women ... reach their 30s, the reverse is true and proportionately more ... Daniel Kruger, a University of Michigan researcher who ...
... may meet criteria for full alert, agency says , TUESDAY, ... H1N1 swine flu in Australia may tip the balance and ... flu pandemic since 1968, agency officials said Tuesday. , Cases ... most occurring in the southern state of Victoria. Rapid spread ...
... be key to a restful night, study finds , TUESDAY, ... and having trouble getting a good night,s sleep, you may ... insomnia reported that they slept better after trying meditation, according ... SLEEP, the annual meeting of the Associated Professional Sleep Societies, ...
Cached Medicine News:Health News:First Brain Training Consumer's Guide Debunks Ten Brain Health Myths and Reviews 21 Products 2Health News:First Brain Training Consumer's Guide Debunks Ten Brain Health Myths and Reviews 21 Products 3Health News:First Brain Training Consumer's Guide Debunks Ten Brain Health Myths and Reviews 21 Products 4Health News:First Brain Training Consumer's Guide Debunks Ten Brain Health Myths and Reviews 21 Products 5Health News:Landmark Study Published in New England Journal of Medicine 2Health News:Landmark Study Published in New England Journal of Medicine 3Health News:When young men are scarce, they're more likely to play the field than to propose 2Health News:WHO Declaration of Swine Flu Pandemic Looks Imminent 2Health News:WHO Declaration of Swine Flu Pandemic Looks Imminent 3Health News:WHO Declaration of Swine Flu Pandemic Looks Imminent 4Health News:WHO Declaration of Swine Flu Pandemic Looks Imminent 5Health News:WHO Declaration of Swine Flu Pandemic Looks Imminent 6Health News:WHO Declaration of Swine Flu Pandemic Looks Imminent 7Health News:WHO Declaration of Swine Flu Pandemic Looks Imminent 8Health News:WHO Declaration of Swine Flu Pandemic Looks Imminent 9Health News:WHO Declaration of Swine Flu Pandemic Looks Imminent 10Health News:WHO Declaration of Swine Flu Pandemic Looks Imminent 11Health News:Meditation May Help Put Primary Insomnia to Bed 2
Straight shafts with teeth and 5 mm tying platform. Wide serrated handle with polished finish. Teeth: 0.3 mm. Manufactured in titanium....
Ergotec Vetriretinal Instrument System. Extra fine angled tips (3 mm). 20 ga. shaft tapering to 23 ga., 10 mm from tip. Overall length from rear rotation knob to tip....
Ergotec Vetriretinal Instrument System. 2 mm pointed black tips with 0.6 mm platform. 20 gauge shaft tapers to 23 gauge....
Ergotec Vetriretinal Instrument System. Ultra-fine 0.8 mm tips. Angled 40 degrees. 20 gauge shaft tapers to 23 gauge....
Medicine Products: